Jul 17, 2020 / 01:30PM GMT
Joshua Brodsky - Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications
Good morning, everyone, and thank you for joining us today for this RNAi Roundtable, where we will be discussing some of our early-stage investigational RNAi therapeutics programs. I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. I'm joined today by Vasant Jadhav, Vice President of Research; Josh Friedman, Senior Director of Clinical Research; and Tanya Fischer, Vice President of Clinical Development. In just a moment, I'll hand it over to Vasant, but let me start quickly with a few brief comments.
Today's RNAi roundtable is part of a series of roundtable webinars that we'll be hosting this summer and early fall to review progress across our various programs. Today's event is expected to run approximately 60 minutes. Vasant will moderate a Q&A session at the conclusion of the presentations. If you'd like to submit a question, you can do so at any time during the event by typing your question in the 'Ask a Question' field. Finally, as a reminder, we will be
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Early Stage RNAi Therapeutics Pipeline Transcript
Jul 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers